{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:39Z","timestamp":1787440959351,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K20787"],"award-info":[{"award-number":["22K20787"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03036"],"award-info":[{"award-number":["22H03036"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K02622"],"award-info":[{"award-number":["25K02622"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K12452"],"award-info":[{"award-number":["25K12452"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15683"],"award-info":[{"award-number":["23K15683"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119637","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:30:37Z","timestamp":1780939837000},"page":"119637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NKG2D-based CAR-T cells for synovial sarcoma: A preclinical proof-of-concept study"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0797-506X","authenticated-orcid":false,"given":"Tomohiro","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-7968","authenticated-orcid":false,"given":"Minori","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7867-1371","authenticated-orcid":false,"given":"Yasushi","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chansu","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4779-272X","authenticated-orcid":false,"given":"Nobuhiro","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ariizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-7517","authenticated-orcid":false,"given":"Keichiro","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-1937","authenticated-orcid":false,"given":"Yiwei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-680X","authenticated-orcid":false,"given":"Masaru","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ogose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-3464","authenticated-orcid":false,"given":"Chihaya","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2026.119637_bib1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/cam4.288","article-title":"Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report","volume":"3","author":"Corey","year":"2014","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119637_bib2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/curroncol28030177","article-title":"Synovial sarcoma: a clinical review","volume":"28","author":"Gazendam","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.biopha.2026.119637_bib3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fonc.2019.01078","article-title":"Epigenetic Targets in Synovial Sarcoma: A Mini-Review","volume":"9","author":"Hale","year":"2019","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119637_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/annonc\/mdq394","article-title":"Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors","volume":"22","author":"Krieg","year":"2011","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119637_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/annonc\/mdi082","article-title":"Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital","volume":"16","author":"Spurrell","year":"2005","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119637_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","article-title":"Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study","volume":"15","author":"Savina","year":"2017","journal-title":"BMC Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119637_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.biopha.2026.119637_bib8","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","article-title":"Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I\/II Clinical Trial","volume":"29","author":"Kawai","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"10435","key":"10.1016\/j.biopha.2026.119637_bib9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.biopha.2026.119637_bib10","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1111\/cas.13769","article-title":"Prognostic impact of the tumor immune microenvironment in synovial sarcoma","volume":"109","author":"Oike","year":"2018","journal-title":"Cancer Sci."},{"issue":"15","key":"10.1016\/j.biopha.2026.119637_bib11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119637_bib12","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119637_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.713158","article-title":"Leveraging NKG2D Ligands in Immuno-Oncology","volume":"12","author":"Fuertes","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119637_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010177","article-title":"Fusion Proteins of NKG2D\/NKG2DL in Cancer Immunotherapy","volume":"19","author":"Ding","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119637_bib15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and Its Ligands: \"One for All, All for One\"","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119637_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fimmu.2019.00661","article-title":"NKG2D\/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment","volume":"10","author":"Frazao","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119637_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199801153380303","article-title":"SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma","volume":"338","author":"Kawai","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119637_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030588","article-title":"Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research","volume":"15","author":"Landuzzi","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119637_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2003.09.031","article-title":"Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1","volume":"204","author":"Kawai","year":"2004","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.biopha.2026.119637_bib20","first-page":"498","article-title":"Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II","volume":"67","author":"Sonobe","year":"1992","journal-title":"Lab. Invest."},{"issue":"7","key":"10.1016\/j.biopha.2026.119637_bib21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/stem.452","article-title":"Synovial sarcoma is a stem cell malignancy","volume":"28","author":"Naka","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.biopha.2026.119637_bib22","article-title":"Integrative analysis of synovial sarcoma transcriptome reveals different types of transcriptomic changes","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.biopha.2026.119637_bib23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ccell.2018.05.002","article-title":"The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma","volume":"33","author":"McBride","year":"2018","journal-title":"Cancer Cell."},{"issue":"6","key":"10.1016\/j.biopha.2026.119637_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16061125","article-title":"Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma Cells","volume":"16","author":"Kotani","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119637_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinforma."},{"issue":"2","key":"10.1016\/j.biopha.2026.119637_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031210","article-title":"Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection","volume":"7","author":"Lehner","year":"2012","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.biopha.2026.119637_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2012.143","article-title":"Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition","volume":"24","author":"Song","year":"2013","journal-title":"Hum. Gene Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119637_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101227","article-title":"Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma","volume":"14","author":"Murayama","year":"2021","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119637_bib29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.biopha.2026.119637_bib30","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/cas.13636","article-title":"alpha-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119637_bib31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ccell.2018.01.018","article-title":"The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma","volume":"33","author":"Banito","year":"2018","journal-title":"Cancer Cell."},{"issue":"19","key":"10.1016\/j.biopha.2026.119637_bib32","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells","volume":"23","author":"Fernandez","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119637_bib33","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3389\/fimmu.2018.02940","article-title":"Overcoming Target Driven Fratricide for T Cell Therapy","volume":"9","author":"Breman","year":"2018","journal-title":"Front. Immunol."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119637_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation","volume":"281","author":"Betts","year":"2003","journal-title":"J. Immunol. Methods"},{"issue":"2","key":"10.1016\/j.biopha.2026.119637_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","article-title":"Relationship between CD107a expression and cytotoxic activity","volume":"254","author":"Aktas","year":"2009","journal-title":"Cell. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119637_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jcyt.2023.10.007","article-title":"Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study","volume":"26","author":"Qian","year":"2024","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.biopha.2026.119637_bib37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"issue":"10","key":"10.1016\/j.biopha.2026.119637_bib38","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jcyt.2013.05.022","article-title":"Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model","volume":"15","author":"Geller","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biopha.2026.119637_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1150765","article-title":"New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas","volume":"13","author":"Seong","year":"2023","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119637_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071125","article-title":"Gene and Cell Therapy for Sarcomas: A Review","volume":"17","author":"Chawla","year":"2025","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.biopha.2026.119637_bib41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10254","key":"10.1016\/j.biopha.2026.119637_bib42","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2026.119637_bib43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2026.119637_bib44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119637_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1777064","article-title":"Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors","volume":"9","author":"Alcantara","year":"2020","journal-title":"Oncoimmunology"},{"issue":"399","key":"10.1016\/j.biopha.2026.119637_bib46","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119637_bib47","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Ralpha2-CAR T Cells but Results in Antigen Loss Variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2026.119637_bib48","doi-asserted-by":"crossref","unstructured":"Han Y., Xie W., Song D.G., Powell D.J., Jr. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11(1):92.","DOI":"10.1186\/s13045-018-0635-z"},{"issue":"11","key":"10.1016\/j.biopha.2026.119637_bib49","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2026.119637_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100735","article-title":"Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers","volume":"31","author":"Chinsuwan","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"issue":"12","key":"10.1016\/j.biopha.2026.119637_bib51","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1038\/s41375-025-02767-4","article-title":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia","volume":"39","author":"Pollyea","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.biopha.2026.119637_bib52","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/bjc.2017.79","article-title":"MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue","volume":"116","author":"Ghadially","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119637_bib53","article-title":"Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119637_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119637_bib55","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:59:14Z","timestamp":1787439554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":55,"alternative-id":["S0753332226006736"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119637","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NKG2D-based CAR-T cells for synovial sarcoma: A preclinical proof-of-concept study","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119637"}}